Construction and validation of a prognostic risk score model for malignant mesothelioma

Discover Oncology 2026 February 8 [Link] Qingzheng An, Fengyun Cui, Guangming Shi, Longkun Ni, Kun Xiao, Feng Tian, Yuezhi Chen, Leping Li, Changqing Jing, Guodong Lian Abstract Purpose: Malignant mesothelioma is a rare, aggressive cancer. Although the World Health Organization (WHO) histologic subtypes–epithelioid (best prognosis), biphasic, and sarcomatoid (worst prognosis)—provide baseline stratification, architectural and molecular…

Read More

Disaster on MARS2? Lessons Learned from Modern Day Outcomes of Surgery for Pleural Mesothelioma

The Annals of Thoracic Surgery 2026 February 2 [Link] Shubham Gulati, Andrea Wolf, Jai Mehrotra-Varma, Stephanie Tuminello, Emanuela Taioli, Raja Flores Abstract Background: The Mesothelioma and Radical Surgery 2 (MARS2) trial has drawn into question pleurectomy/decortication (PD) for the treatment of pleural mesothelioma. This trial’s evaluation of resectability (poor positron emission tomography/computed tomography utilization, patients…

Read More

Neoadjuvant Pressurized Intraperitoneal Aerosol Chemotherapy for Conversion to Cytoreductive Surgery in Unresectable Malignant Peritoneal Mesothelioma: A Report of 2 Cases

The American Journal of Case Reports 2026 February [Link] Arnaldo Urbano-Ruiz, Bruna Latronico Palma, Ronaldo Elias Carnut Rego, Daniel Bianqui Guaraldo da Silva, Bianca Fava, Erlan Araujo Falcão , Michelle Louise Rodrigues Barbosa da Silva, Julia Rodrigues Leandro Uliano Abstract BACKGROUND Peritoneal mesothelioma (PM) is the second most common presentation site of malignant mesothelioma. The…

Read More

Adverse Renal Outcomes in Patients With Mesothelioma-A Territory-Wide Real-World Data

Cancer Medicine 2026 February [Link] Wang Chun Kwok, James Chung Man Ho, Isaac Sze Him Leung, Desmond Yat Hin Yap Abstract Introduction: Advances in mesothelioma management have translated into longer patient survival and different treatment-related side effects including nephrotoxicity. The risk of developing adverse renal outcomes in patients with mesothelioma and associated risk factors remains…

Read More

Clinical applications of cryobiopsy in the diagnosis of thoracic malignancies: a comprehensive review

Japanese Journal of Clinical Oncology 2026 January 30 [Link] Miwa Kamatani, Nobuyasu Awano, Takehiro Izumo Abstract Accurate histopathological and molecular characterization of lung cancer is essential for optimal treatment selection in the era of precision medicine. While conventional biopsy techniques are widely available and safe, they often yield small tissue samples with crush artifacts that…

Read More

Treatment Patterns, Clinical Outcomes, Health Care Resource Use, and Costs in Older Adults with Malignant Pleural Mesothelioma in the United States, 2007-2020

Advances in Therapy 2026 March [Link] Himani Aggarwal, Ashwini Arunachalam, Jae Min, Yu-Han Kao, Haidong Feng, Danmeng Huang, Gloria Odonkor Abstract Introduction: Malignant pleural mesothelioma (MPM) is a rare malignancy typically attributed to occupational asbestos exposure and associated with dismal survival outcomes. The standard of care for unresectable MPM was platinum-based chemotherapy until the approval…

Read More

Pembrolizumab Plus Platinum Doublet Chemotherapy With Lenvatinib in Unresectable Pleural Mesothelioma as First-Line Treatment (PENINSULA): A Study Protocol for a Single-Arm, Multi-Institutional, Phase II Clinical Trial

Clinical Lung Cancer 2026 March [Link] Tetsuya Takagawa, Kanae Takahashi, Yuji Orimoto, Yukie Morisaki, Shinichiro Suna, Takashi Daimon, Takashi Kijima, Kozo Kuribayashi Abstract Background: In pleural mesothelioma (PM), platinum-based chemotherapy and immune checkpoint inhibitors including nivolumab and ipilimumab have been approved but have not shown sufficient therapeutic efficacy, and the development of new therapies is…

Read More

Mechanisms of Chemoresistance in Malignant Pleural Mesothelioma: The Regulatory Role of miRNAs

Archives of Medical Research 2026 January 27 [Link] Andrea Martinez-Marroquin, Javier Gaytán-Cervantes, Haydeé Rosas-Vargas, Constantino López-Macías, Itzel Peralta-Salguero, Miguel Cid-Soto, Violeta Castro Leyva, Marlon De Ita, Carolina González-Torres Abstract Malignant pleural mesothelioma (MPM), is a rare and aggressive cancer that originates in the mesothelium lining the lungs. It is considered an occupational disease associated with…

Read More

Evaluation of respiratory toxicity and peritoneal mesothelioma induced by heat-treated and milled amosite following intratracheal and intraperitoneal injection in rats

Industrial Health 2026 January 29 [Link] Hiroshi Yamauchi, Ayako Takata, Kiyotsugu Yamashita, Masahito Aminaka, Toshiaki Hitomi, Norihiko Kohyama Abstract Amoste is highly carcinogenic, and its incomplete removal from the environment continues to pose significant health risks. High temperatures are known to alter the crystal structure of asbestos. In this study, we evaluated the carcinogenicity and…

Read More

Time to next procedure in patients with malignant pleural effusion undergoing aspiration: derivation and initial validation of the RED score

Thorax 2026 January 28 [Link] Eleanor K Mishra, Helen Davies, Syed Hamza Abbas, Cheryl Hardy, Dominic T Beith, Dheeraj Sethi, Toshit Sapkal, Alguili Elsheikh, Asfandyar Yousuf, Emma L Hedley, Ellie Daly, Anand Sundaralingam, Dinesh Addala, Samantha A Jones, Lianne Castle, Neena Patel, Jurgen Herre, Hannah Collins, Jack Kastelik, Clare L Ross, John Corcoran, Cyrus Daneshvar,…

Read More